- Design
- Cross-sectional pharmacokinetic and pharmacogenetic study
- Population
- 102 Japanese patients with lupus on hydroxychloroquine
- Primary outcome
- Low disease activity (SLEDAI-2K ≤4, prednisolone ≤5 mg/day)
- Effect
- Plasma metabolite aOR 1.80 per SD (95% CI 1.10–2.95); parent drug not associated; AUC 0.62–0.67
A Japanese study measured hydroxychloroquine and its active metabolite desethylhydroxychloroquine in 102 patients with lupus on treatment for at least six months, genotyped CYP2D6 and CYP3A5, and related exposure to low disease activity (SLEDAI-2K of 4 or less on prednisolone 5 mg or less).
The 23% who were CYP2D6 intermediate metabolisers made proportionately less metabolite. Hydroxychloroquine levels themselves, and genotype alone, were not associated with disease control. Higher metabolite concentrations and metabolite-to-parent ratios were (adjusted OR 1.80 per SD for plasma metabolite, 95% CI 1.10–2.95; 2.36 for whole-blood ratio).
Discrimination was modest (AUC 0.62–0.67), and this is a cross-sectional study in one population. The finding is a candidate marker, not a test to order. It does suggest one reason two patients on the same dose can respond differently.
- Hydroxychloroquine levels alone were not linked to lupus control in this study
- The active metabolite, influenced by CYP2D6 genotype, was
- Do not order genotyping or metabolite levels routinely on this evidence
- Keep monitoring adherence — the commonest reason for low drug exposure
Why it matters
It suggests why the same dose leaves some patients controlled and others not.
Don't overread it
This is a cross-sectional study with modest discrimination; it needs prospective validation before changing monitoring.
The statistics, in plain English
An odds ratio of 1.80 per standard deviation means each step up in metabolite concentration was associated with 80% higher odds of low disease activity. An AUC around 0.65 means the marker separates patients only weakly.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for clinical pharmacology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free